文献速递放疗物理与技术消化道肿瘤放疗泌尿生殖与妇科肿瘤放疗

建立双CT与MR引导自适应放疗项目的初步临床经验

Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-07-22

本文回顾某机构在2021年10月至2022年9月一年内建立双模态自适应放疗(ART)项目的经验。共256例患者接受自适应放疗意向治疗,其中MR引导自适应放疗(MRgART)186例、CT引导自适应放疗(CTgART)70例;MRgART以胰腺癌为主(106/186),CTgART常见部位为盆腔(23/70)和腹部(20/70)。MRgART平台93.0%的治疗为立体定向体部放疗(SBRT),CTgART平台为72.9%;该项目已促成6项使用MRgART和7项使用CTgART的开放性临床试验。

要点

  • 一年内共256例患者接受自适应放疗意向治疗,MRgART 186例,CTgART 70例。
  • MRgART以胰腺癌为主(106/186),CTgART常见部位为盆腔(23/70)和腹部(20/70)。
  • MRgART平台93.0%的治疗为SBRT,CTgART平台为72.9%。

核心结论

  • 本机构成功建立了双平台自适应放疗项目,需持续努力以跨平台和跨病种整合自适应放疗,以最大化该技术的可及性和证据。

研究设计与样本

  • 单机构经验总结,分析2021年10月至2022年9月一年内接受自适应放疗意向治疗的患者和治療信息,包括治疗病种、放疗剂量与分次、治疗时间,并回顾本机构建立、验证和实施新自适应工作流程的流程。

主要发现

  • 2021年10月至2022年9月,共256例患者接受自适应放疗意向治疗,其中MRgART 186例,CTgART 70例。
  • MRgART治疗患者中多数为胰腺癌(106/186),CTgART最常见治疗部位为盆腔(23/70)和腹部(20/70)。
  • MRgART平台93.0%的治疗为SBRT,CTgART平台72.9%的治疗为SBRT。
  • 腹部门控病例在CTgART平台分配的时间长于MRgART平台,盆腔病例在CTgART平台分配的时间短于MRgART平台。
  • 本机构的自适应实施技术已促成6项使用MRgART和7项使用CTgART的开放性临床试验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Our institution was the first in the world to clinically implement MR-guided adaptive radiotherapy (MRgART) in 2014. In 2021, we installed a CT-guided adaptive radiotherapy (CTgART) unit, becoming one of the first clinics in the world to build a dual-modality ART clinic. Herein we review factors that lead to the development of a high-volume dual-modality ART program and treatment census over an initial, one-year period. MATERIALS AND METHODS: The clinical adaptive service at our institution is enabled with both MRgART (MRIdian, ViewRay, Inc, Mountain View, CA) and CTgART (ETHOS, Varian Medical Systems, Palo Alto, CA) platforms. We analyzed patient and treatment information including disease sites treated, radiation dose and fractionation, and treatment times for patients on these two platforms. Additionally, we reviewed our institutional workflow for creating, verifying, and implementing a new adaptive workflow on either platform. RESULTS: From October 2021 to September 2022, 256 patients were treated with adaptive intent at our institution, 186 with MRgART and 70 with CTgART. The majority (106/186) of patients treated with MRgART had pancreatic cancer, and the most common sites treated with CTgART were pelvis (23/70) and abdomen (20/70). 93.0% of treatments on the MRgART platform were stereotactic body radiotherapy (SBRT), whereas only 72.9% of treatments on the CTgART platform were SBRT. Abdominal gated cases were allotted a longer time on the CTgART platform compared to the MRgART platform, whereas pelvic cases were allotted a shorter time on the CTgART platform when compared to the MRgART platform. Our adaptive implementation technique has led to six open clinical trials using MRgART and seven using CTgART. CONCLUSIONS: We demonstrate the successful development of a dual platform ART program in our clinic. Ongoing efforts are needed to continue the development and integration of ART across platforms and disease sites to maximize access and evidence for this technique worldwide.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Price AT, Schiff JP, Laugeman E, et al. Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program. Clin Transl Radiat Oncol. 2023. PMID: 37529627. doi:10.1016/j.ctro.2023.100661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。